Boston Scientific resumes enrolment in pulsed field ablation trial
Boston Scientific has resumed enrolment for its AVANT GUARD clinical trial, after it was paused in October 2024to “assess a …
Boston Scientific has resumed enrolment for its AVANT GUARD clinical trial, after it was paused in October 2024to “assess a …
Nammi Therapeutics has commenced the first in-human Phase I trial of QXL138AM by dosing the first subject for treating advanced …
Boston-based Paratek Pharmaceuticals has released positive topline data from a Phase IIb trial evaluating its oral antibiotic Nuzyra (omadacycline) in …
Palleon Pharmaceuticals has reported the outcomes from its Phase I/II study of E-602 along with programmed death (PD)-1 inhibitor cemiplimab …
Leading sales and marketing intent data, database and data enrichment providers and technology solutions for the clinical trials industry: introduction In …
Boston Scientific has resumed enrolment for its AVANT GUARD clinical trial, after it was paused in October 2024to “assess a …
Nammi Therapeutics has commenced the first in-human Phase I trial of QXL138AM by dosing the first subject for treating advanced …
Boston-based Paratek Pharmaceuticals has released positive topline data from a Phase IIb trial evaluating its oral antibiotic Nuzyra (omadacycline) in …
Palleon Pharmaceuticals has reported the outcomes from its Phase I/II study of E-602 along with programmed death (PD)-1 inhibitor cemiplimab …
Leading sales and marketing intent data, database and data enrichment providers and technology solutions for the clinical trials industry: introduction In …
Spectral Medical will have to wait to submit an application to the US Food and Drug Administration (FDA) for its …
The pharmaceutical industry is on the brink of a remarkable transformation over the next ten years. As the demand for …
OncoResponse has unveiled the outcomes from the Phase I trial of OR502, a humanised anti-leukocyte immunoglobulin like receptor B2 (LILRB2) …
A target product profile (TPP) is a set of necessary attributes that the final drug product must have for the …
AstraZeneca and Amgen have released topline data from a Phase III trial of its inflammatory therapy, Tezspire (tezepelumab) in patients …